NewLink Genetics Announces Presentation of Two Abstracts at ASCO
April 21 2017 - 7:00AM
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical
company focused on bringing novel immuno-oncology therapies to
patients with cancer, today reported that two abstracts will be
presented at the 2017 American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago.
- Abstract 105 - A Phase 1b dose-escalation
study of combined inhibition of IDO1 (GDC-0919) and PD-L1
(atezolizumab) in patients (pts) with locally advanced or
metastatic solid tumors, to be presented by our partner on Sunday,
June 4, 2017, 10:45 a.m. – 12:15 p.m. ET.
- Abstract 3066 - A Phase 2 randomized,
double-blind study of sipuleucel-T followed by IDO pathway
inhibitor, indoximod, or placebo in the treatment of patients with
metastatic castration resistant prostate cancer (mCRPC), to be
presented on Monday, June 5, 2017, 9:00 a.m. – 12:30 p.m. ET.
The complete text of the abstracts will be posted online at 5:00
p.m. ET on Wednesday, May 17.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront
of discovering, developing and commercializing novel
immuno-oncology product candidates to improve the lives of patients
with cancer. NewLink Genetics' product candidates are designed to
harness multiple components of the immune system to combat
cancer. For more information, please visit
http://www.newlinkgenetics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking statements of
NewLink Genetics that involve substantial risks and uncertainties.
All statements, other than statements of historical facts,
contained in this press release are forward-looking statements,
within the meaning of The Private Securities Litigation Reform Act
of 1995. The words "anticipate," "believe," "estimate," "expect,"
"intend," "may," "plan," "target," "potential," "will," "could,"
"should," "seek" or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include any
statements other than statements of historical fact. Actual results
or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that
NewLink Genetics makes due to a number of important factors,
including those risks discussed in "Risk Factors" and elsewhere in
NewLink Genetics' Annual Report on Form 10-K for the year ended
December 31, 2016 and other reports filed with the U.S. Securities
and Exchange Commission (SEC). The forward-looking statements in
this press release represent NewLink' Genetics' views as of the
date of this press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink Genetics' views
as of any date subsequent to the date of this press release.
Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
(515) 598-2555
lmiller@linkp.com
Investor Contact:
Beth Kurth, VP
LaVoieHealthScience
(617) 374-8800, ext. 106
bkurth@lavoiehealthscience.com
Media Contact:
Sharon Correia, VP
LaVoieHealthScience
(617) 374-8800, ext. 105
scorreia@lavoiehealthscience.com
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024